Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT06375707
What this trial is testing

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Not applicableStudy completedNCT02521363
What this trial is testing

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 11
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Not applicableUnknownNCT04852081
What this trial is testing

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Who this might be right for
Breast Cancer Stage IV
Blokhin's Russian Cancer Research Center 1,000
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Not applicableLooking for participantsNCT06328465
What this trial is testing

FREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

Who this might be right for
Invasive Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
European Institute of Oncology 145
Testing effectiveness (Phase 2)UnknownNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)Study completedNCT00960336
What this trial is testing

Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
ARCAGY/ GINECO GROUP 59
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410234
What this trial is testing

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 110
Not applicableEnded earlyNCT01957514
What this trial is testing

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+2 more
University of Washington 31
Not applicableActive Not RecruitingNCT05939128
What this trial is testing

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Who this might be right for
Breast Cancer
AstraZeneca 625
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Testing effectiveness (Phase 2)Looking for participantsNCT04348747
What this trial is testing

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute 23
Testing effectiveness (Phase 2)WithdrawnNCT04038489
What this trial is testing

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
University of Virginia
Next Page